retatrutide glp-1 receptor agonist | GLP-1R/GIPR/GCGR ligand | Sterile Retatrutide for weight loss: Study
Description
This has folks wondering what it will cost in the future and whether it will be priced on par or below drugs like Ozempic
Ready to talk options
Lilly currently holds an advantage with Zepbounds approval for obstructive sleep apnea (OSA) , but Novo is running late-stage trials to close that gap
The FDA followed up a January 2025 inspection with a warning letter to California -based Oasis Medical, Inc
This isnt patient protection
